OTCMKTS:MDGEF Medigene (MDGEF) Stock Price, News & Analysis → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free MDGEF Stock Alerts $2.43 0.00 (0.00%) (As of 05/30/2024 ET) Add Compare Share Share Today's Range$2.43▼$2.4350-Day Range$2.43▼$2.7652-Week Range$1.50▼$2.84VolumeN/AAverage Volume600 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About MedigeneMedigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More MDGEF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGEF Stock News HeadlinesMay 28 at 3:00 AM | globenewswire.comMedigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent OfficeMay 14, 2024 | globenewswire.comMedigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital RaiseMay 2, 2024 | globenewswire.comMedigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell ReceptorApril 26, 2024 | globenewswire.comMedigene AG reports Financial Results and Business Update for Q1 2024April 4, 2024 | globenewswire.comMedigene AG Secures European Patent for its iM-TCR TechnologyMarch 28, 2024 | globenewswire.comMedigene AG Reports Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | globenewswire.comMedigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 18, 2024 | globenewswire.comMedigene AG to report full year 2023 financial results on March 28, 2024March 4, 2024 | globenewswire.comMedigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In VivoSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MDGEF CUSIPN/A CIKN/A Webwww.medigene.com Phone(989) 200-0330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesDr. Selwyn Ho MB BS (Age 53)MBBS, CEO & Member of Executive Management Board Comp: $418.04kDr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & DevelopmentDr. Ernst-Ludwig Winnacker (Age 83)Co-Founder & Chairman Scientific Advisory Board Comp: $21.75kDr. Birger KohlertChief Financial OfficerPamela KeckVice President of Investor Relations & Corporate CommunicationsDr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MDGEF Stock Analysis - Frequently Asked Questions How have MDGEF shares performed in 2024? Medigene's stock was trading at $1.50 at the start of the year. Since then, MDGEF stock has increased by 62.0% and is now trading at $2.43. View the best growth stocks for 2024 here. Are investors shorting Medigene? Medigene saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 9,200 shares, a drop of 33.8% from the April 15th total of 13,900 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days. View Medigene's Short Interest. How do I buy shares of Medigene? Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MDGEF) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist My Default Watchlist Adding Medigene AG You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.